Among breast cancer patients with higher residual disease burden after neoadjuvant therapy for HR+/HER2− breast cancer, patients with high-level expression of ROR1 had significantly worse event-free survival than those with low-level expression of ROR1 [12]. This evidence concerns the gene ROR1 and breast carcinoma.